AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Palo Alto Networks CEO: “We’re happy Wiz is now part of Google, it gives us more room to operate”
2
“Younger people are getting cancer more and more. We have to make kinder medicines.”
3
The $2.3 billion mystery arms deal Israel won’t explain
4
“The acquisition of Armis marks a clear entry by ServiceNow into cybersecurity”
5
Navan shares extend decline as losses widen and CFO plans exit
More news

CytoReason

4 stories about CytoReason
דוד הראל מייסד מנכ"ל CytoReason

CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models

17.07.24|Meir Orbach
The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio. 
מייסדי סייטוריזן, מימין: דוד הראל, פרופ' שי שן-אור, אלינה סטרוסבצקי, רנו גוז'ו

CytoReason raises $20 million from Pfizer for AI drug discovery and development platform

20.09.22|Meir Orbach
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
David Harel CytoReason

CytoReason enters Japanese market with SPI partnership

30.09.21|James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason

10.01.19|Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars